相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema
Chirag D. Jhaveri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema
Rohit Varma et al.
CLINICAL OPHTHALMOLOGY (2020)
Intravitreal Aflibercept for Diabetic Macular Edema 148-Week Results from the VISTA and VIVID Studies
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2016)
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial
John A. Wells et al.
OPHTHALMOLOGY (2016)
Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial
Eric L. Ross et al.
JAMA OPHTHALMOLOGY (2016)
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
John A. Wells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy Long-Term Outcomes of the Phase III RIDE and RISE Trials
David S. Boyer et al.
OPHTHALMOLOGY (2015)
Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results
Michael J. Elman et al.
OPHTHALMOLOGY (2015)
Switching To Less Expensive Blindness Drug Could Save Medicare Part B $18 Billion Over A Ten-Year Period
David Hutton et al.
HEALTH AFFAIRS (2014)
ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines
Jeffrey L. Anderson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold
Peter J. Neumann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial
Paul Mitchell et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2012)
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Scott D Grosse
Expert Review of Pharmacoeconomics & Outcomes Research (2008)
Health care economic analyses and value-based medicine
MM Brown et al.
SURVEY OF OPHTHALMOLOGY (2003)
分享论文
